Production of recombinant TSA-1 and evaluation of its potential for the immuno-therapeutic control of Trypanosoma cruzi infection in mice

References

• Global Burden of Disease. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390:1211–1259. doi:10.1016/S0140-6736(17)32154-2.
   PubMed Web of Science ®Google Scholar
• Global Burden of Disease. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385:117–171. doi:10.1016/S0140-6736(14)61682-2.
   PubMed Web of Science ®Google Scholar
• Hotez PJ, Alvarado M, Basanez MG, Bolliger I, Bourne R, Boussinesq M, Brooker SJ, Brown AS, Buckle G, Budke CM, et al. The global burden of disease study 2010: interpretation and implications for the neglected tropical diseases. PLoS Negl Trop Dis. 2014;8:e2865. doi:10.1371/journal.pntd.0002865.
   PubMed Web of Science ®Google Scholar
• WHO. Chagas disease in Latin America: an epidemiological update based on 2010 estimates. Weekly Epidemiol Rec. 2015;90:33–43.
   PubMedGoogle Scholar
• Pecoul B, Batista C, Stobbaerts E, Ribeiro I, Vilasanjuan R, Gascon J, inazo MJ, Moriana S, Gold S, Pereiro A, et al. The BENEFIT Trial: where do we go from here?. PLoS Negl Trop Dis. 2016;10:e0004343. doi:10.1371/journal.pntd.0004343.
   PubMed Web of Science ®Google Scholar
• Antunes AP, Ribeiro AL, Sabino EC, Silveira MF, Oliveira CD, Botelho AC. Benznidazole therapy for Chagas disease in asymptomatic Trypanosoma cruzi -seropositive former blood donors: evaluation of the efficacy of different treatment regimens. Rev Soc Bras Med Trop. 2016;49:713–720. doi:10.1590/0037-8682-0165-2016.
   PubMed Web of Science ®Google Scholar
• Antinori S, Grande R, Bianco R, Traversi L, Cogliati C, Torzillo D, Repetto E, Corbellino M, Milazzo L, Gali M, et al. High frequency of adverse reactions and discontinuation with benznidazole treatment for chronic Chagas disease in Milano, Italy. Clin Infect Dis. 2015;60:1873–1875. doi:10.1093/cid/civ230.
   PubMed Web of Science ®Google Scholar
• Morillo CA, Marin-Neto JA, Avezum A, Sosa-Estani S, Rassi A, Jr., Rosas F, Villena E, Quiroz R, Bonilla R, Britto C, et al. Randomized trial of benznidazole for chronic chagas’ cardiomyopathy. New England J Med. 2015;373:1295–1306. doi:10.1056/NEJMoa1507574.
   PubMed Web of Science ®Google Scholar
• Morillo CA, Waskin H, Sosa-Estani S, Del Carmen Bangher M, Cuneo C, Milesi R, Mallagray M, Apt W, Beloscar J, Gascon J, et al. Benznidazole and posaconazole in eliminating parasites in asymptomatic T. Cruzi carriers: the STOP-CHAGAS Trial. J Am Coll Cardiol. 2017;69:939–947. doi:10.1016/j.jacc.2016.12.023.
   PubMed Web of Science ®Google Scholar
• Murcia L, Carrilero B, Ferrer F, Roig M, Franco F, Segovia M. Success of benznidazole chemotherapy in chronic Trypanosoma cruzi-infected patients with a sustained negative PCR result. Eur J Clin Micro & Infect Dis. 2016;35:1819–1827. doi:10.1007/s10096-016-2733-6.
   PubMed Web of Science ®Google Scholar
• Lee BY, Bacon KM, Wateska AR, Bottazzi ME, Dumonteil E, Hotez PJ. Modeling the economic value of a chagas’ disease therapeutic vaccine. Hum Vaccines Immunother. 2012;8:1293–1301. doi:10.4161/hv.20966.
   PubMed Web of Science ®Google Scholar
• Lee BY, Bacon KM, Connor DL, Willig AM, Bailey RR. The potential economic value of a Trypanosoma cruzi (Chagas disease) vaccine in Latin America. PLoS Negl Trop Dis. 2010;4:e916. doi:10.1371/journal.pntd.0000916.
   PubMed Web of Science ®Google Scholar
• Quijano-Hernandez I, Dumonteil E. Advances and challenges towards a vaccine against Chagas disease. Human Vaccines. 2011;7:1184–1191. doi:10.4161/hv.7.11.17016.
   PubMed Web of Science ®Google Scholar
• Dumonteil E, Bottazzi ME, Zhan B, Heffernan MJ, Jones K, Valenzuela JG, Kamhawi S, Ortega J, Rosales SP, Lee BY, et al. Accelerating the development of a therapeutic vaccine for human Chagas disease: rationale and prospects. Expert Rev Vaccines. 2012;11:1043–1055. doi:10.1586/erv.12.85.
   PubMed Web of Science ®Google Scholar
• Dumonteil E, Escobedo-Ortegon J, Reyes-Rodriguez N, Ramirez-Sierra MJ, Arjona-Torres A. Immunotherapy of Trypanosoma cruzi infection with DNA vaccines in mice. Infect & Immun. 2004;72:46–53. doi:10.1128/IAI.72.1.46-53.2004.
   PubMed Web of Science ®Google Scholar
• Limon-Flores AY, Cervera-Cetina R, Tzec-Arjona JL, Ek-Macias L, Sanchez-Burgos G, Ramirez-Sierra MJ, Cruz-Chan JV, VanWynsberghe NR, Dumonteil E. Effect of a combination DNA vaccine for the prevention and therapy of Trypanosoma cruzi infection in mice: role of CD4+ and CD8+ T cells. Vaccine. 2010;28:7414–7419. doi:10.1016/j.vaccine.2010.08.104.
   PubMed Web of Science ®Google Scholar
• Sanchez-Burgos G, Mezquita-Vega G, Escobedo-Ortegon J, Ramirez-Sierra MJ, Arjona-Torres A, Rodrigues MM, Ouaissi A, Dumonteil E. Comparative efficacy of DNA vaccines encoding various Trypanosoma cruzi antigens. FEMS Microbiol Med Immunol. 2007;50:333–341. doi:10.1111/j.1574-695X.2007.00251.x.
   PubMed Web of Science ®Google Scholar
• Zapata-Estrella H, Hummel-Newell C, Sanchez-Burgos G, Escobedo-Ortegon J, Ramirez-Sierra MJ, Arjona-Torres A, Dumonteil E. Control of Trypanosoma cruzi infection and changes in T cell populations induced by a therapeutic DNA vaccine in mice. Immunol Lett. 2006;103:186–191. doi:10.1016/j.imlet.2005.11.015.
   PubMed Web of Science ®Google Scholar
• Quijano-Hernandez IA, Castro-Barcena A, Vazquez-Chagoyan JC, Bolio-Gonzalez ME, Ortega-Lopez J, Dumonteil E. Preventive and therapeutic DNA vaccination partially protect dogs against an infectious challenge with Trypanosoma cruzi. Vaccine. 2013;31:2246–2252. doi:10.1016/j.vaccine.2013.03.005.
   PubMed Web of Science ®Google Scholar
• Quijano-Hernandez IA, Bolio-González ME, Rodríguez-Buenfil JC, Ramirez-Sierra MJ, Dumonteil E. Therapeutic DNA vaccine against Trypansomoma cruzi in dogs: a pilot clinical trial. Ann N Y Acad Sci. 2008;1149:343–346. doi:10.1196/annals.1428.098.
   PubMed Web of Science ®Google Scholar
• Porter KR, Raviprakash K. DNA vaccine delivery and improved immunogenicity. Curr Issues Mol Biol. 2017;22:129–138. doi:10.21775/cimb.022.129.
   PubMed Web of Science ®Google Scholar
• Martinez-Campos V, Martinez-Vega P, Ramirez-Sierra MJ, Rosado-Vallado M, Seid CA, Hudspeth EM, Wei J, Liu Z, Kwityn C, Hammond M, et al. Expression, purification, immunogenicity, and protective efficacy of a recombinant Tc24 antigen as a vaccine against Trypanosoma cruzi infection in mice. Vaccine. 2015;33:4505–4512. doi:10.1016/j.vaccine.2015.07.017.
   PubMed Web of Science ®Google Scholar
• Barry MA, Wang Q, Jones KM, Heffernan MJ, Buhaya MH, Beaumier CM, eegan BP, Zhan B, Dumonteil E, Bottazzi ME, et al. A therapeutic nanoparticle vaccine against Trypanosoma cruzi in a BALB/c mouse model of Chagas disease. Human Vaccines & Immunother. 2016;12:976–987. doi:10.1080/21645515.2015.1119346.
   PubMed Web of Science ®Google Scholar
• Konduri V, Halpert MM, Liang D, Levitt JM, Cruz-Chan JV, Zhan B, Bottazzi ME, Hotez PJ, Jones KM, Decker WK. Genetic adjuvantation of a cell-based therapeutic vaccine for amelioration of chagasic cardiomyopathy. Infect & Immun. 2017;85e00127-17.
   Web of Science ®Google Scholar
• Pereira-Chioccola VL, Schenkman S. Biological role of Trypanosoma cruzi trans-sialidase. Biochem Soc Trans. 1999;27:516–518.
   PubMed Web of Science ®Google Scholar
• Schenkman S, Eichinger D, Pereira ME, Nussenzweig V. Structural and functional properties of Trypanosoma trans-sialidase. Annu Rev Microbiol. 1994;48:499–523. doi:10.1146/annurev.mi.48.100194.002435.
   PubMed Web of Science ®Google Scholar
• Wizel B, Nunes M, Tarleton RL. Identification of Trypanosoma cruzi trans-sialidase family members as targets of protective CD8+ TC1 responses. J Immunol. 1997;159:6120–6130.
   PubMed Web of Science ®Google Scholar
• Costa F, Franchin G, Pereira-Chioccola VL, Ribeirao M, Schenkman S, Rodrigues MM. Immunization with a plasmid DNA containing the gene of trans-sialidase reduces Trypanosoma cruzi infection in mice. Vaccine. 1998;16:768–774.
   PubMed Web of Science ®Google Scholar
• Costa F, Pereira-Chioccola VL, Ribeirao M, Schenkman S, Rodrigues MM. Trans-sialidase delivered as a naked DNA vaccine elicits an immunological response similar to a Trypanosoma cruzi infection. Braz J Med Biol Res. 1999;32:235–239.
   PubMed Web of Science ®Google Scholar
• Fujimura AE, Kinoshita SS, Pereira-Chioccola VL, Rodrigues MM. DNA sequences encoding CD4+ and CD8+ T-cell epitopes are important for efficient protective immunity induced by DNA vaccination with a Trypanosoma cruzi gene. Infect & Immun. 2001;69:5477–5486. doi:10.1128/IAI.69.9.5477-5486.2001.
   PubMed Web of Science ®Google Scholar
• Vasconcelos JR, Hiyane MI, Marinho CR, Claser C, Machado AM, Gazzinelli RT, Gazzinelli RT, Bruna-Romero O, Alvarez JM, Boscardin SB, et al. Protective immunity against Trypanosoma cruzi infection in a highly susceptible mouse strain after vaccination with genes encoding the amastigote surface protein-2 and trans-sialidase. Hum Gene Ther. 2004;15:878–886. doi:10.1089/hum.2004.15.878.
   PubMed Web of Science ®Google Scholar
• Hoft DF, Eickhoff CS, Giddings OK, Vasconcelos JR, Rodrigues MM. Trans-sialidase recombinant protein mixed with CpG motif-containing oligodeoxynucleotide induces protective mucosal and systemic trypanosoma cruzi immunity involving CD8+ CTL and B cell-mediated cross-priming. J Immunol. 2007;179:6889–6900.
   PubMed Web of Science ®Google Scholar
• Wrightsman RA, Dawson BD, Fouts DL, Manning JE. Identification of immunodominant epitopes in Trypanosoma cruzi trypomastigote surface antigen-1 protein that mask protective epitopes. J Immunol. 1994;153:3148–3154.
   PubMed Web of Science ®Google Scholar
• Mizutani H, Sugawara H, Buckle AM, Sangawa T, Miyazono KI, Ohtsuka J, Nagata K, Shojima T, Nosaki S, Xu Y, et al. REFOLDdb: a new and sustainable gateway to experimental protocols for protein refolding. BMC Struct Biol. 2017;17:4. doi:10.1186/s12900-017-0074-z.
   PubMed Web of Science ®Google Scholar
• Antonio-Perez A, Ramon-Luing LA, Ortega-Lopez J. Chromatographic refolding of rhodanese and lysozyme assisted by the GroEL apical domain, DsbA and DsbC immobilized on cellulose. J Chromatogr A. 2012;1248:122–129. doi:10.1016/j.chroma.2012.05.086.
   PubMed Web of Science ®Google Scholar
• Jungbauer A, Kaar W, Schlegl R. Folding and refolding of proteins in chromatographic beds. Curr Opin Biotechnol. 2004;15:487–494. doi:10.1016/j.copbio.2004.08.009.
   PubMed Web of Science ®Google Scholar
• Middelberg AP. Preparative protein refolding. Trends Biotechnol. 2002;20:437–443.
   PubMed Web of Science ®Google Scholar
• Zimmermann S, Egeter O, Hausmann S, Lipford GB, Röcken M, Wagner H, Heeg K. CpG oligodeoxynucleotides trigger protective and curative Th1 responses in lethal murine leishmaniasis. J Immunol. 1998;160:3627–3630.
   PubMed Web of Science ®Google Scholar
• Flynn B, Wang V, Sacks DL, Seder RA, Verthelyi D. Prevention and treatment of cutaneous leishmaniasis in primates by using synthetic type D/A oligodeoxynucleotides expressing CpG motifs. Infect & Immun. 2005;73:4948–4954. doi:10.1128/IAI.73.8.4948-4954.2005.
   PubMed Web of Science ®Google Scholar
• Dumonteil E, Escobedo-Ortegon J, Reyes-Rodriguez N, Arjona-Torres A, Ramirez-Sierra MJ. Immunotherapy of Trypanosoma cruzi infection with DNA vaccines in mice. Infect & Immun. 2004;72:46–53. doi:10.1128/IAI.72.1.46-53.2004.
   PubMed Web of Science ®Google Scholar
• Mata-Haro V, Cekic C, Martin M, Chilton PM, Casella CR, Mitchell TC. The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. Science. 2007;316:1628–1632. doi:10.1126/science.1138963.
   PubMed Web of Science ®Google Scholar
• Rosado-Vallado M, Mut-Martin M, Garcia-Miss MR, Dumonteil E. Aluminium phosphate potentiates DNA vaccines against Leishmania mexicana. Vaccine. 2005;23:5372–5379. doi:10.1016/j.vaccine.2005.05.037.
   PubMed Web of Science ®Google Scholar
• Ishizaka ST, Hawkins LD. E6020: a synthetic Toll-like receptor 4 agonist as a vaccine adjuvant. Expert Rev Vaccines. 2007;6:773–784. doi:10.1586/14760584.6.5.773.
   PubMed Web of Science ®Google Scholar